Anti-tumour necrosis factor-α therapy for rheumatoid and other inflammatory arthropathies: Update on safety in older patients

Drugs and Aging

Volumn 23, Issue 11, 2006, Pages 855-860

  Ornetti, Paul ^a,b   Chevillotte, Hélène ^a   Zerrak, Amal ^a   Maillefert, Jean Francis ^a,b,c  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c HÔPITAL DU BOCAGE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

AGING; ANKYLOSING SPONDYLITIS; ARTHROPATHY; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; COMORBIDITY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; INFECTION; INFECTION RATE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SEPTICEMIA; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS; ARTHRITIS, RHEUMATOID; HUMANS; RANDOMIZED CONTROLLED TRIALS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33751250151     PISSN: 1170229X     EISSN: 1170229X     Source Type: Journal    
DOI: 10.2165/00002512-200623110-00001     Document Type: Review

References (43)

1. Harriman G, Harper LK, Schaible TF. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFα treatment. Ann Rheum Dis 1999; 58 Suppl. I: I61-4
2. Hochberg MC, Tracy JK, Flores RH. "Stepping-up" from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate. Ann Rheum Dis 2001; 60 Suppl. 3: iii51-4
3. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-602
4. Brandt J, Sieper J, Braun J. Infliximab in the treatment of active and severe ankylosing spondylitis. Clin Exp Rheumatol 2002; 20 Suppl. 28: S106-10
5. Braun J, Brandt J, Listing J, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003; 48 (8): 2224-33
6. Schnarr S, Kuipers JG, Zeidler H. Anti-tumour necrosis factor (TNF)-α therapy in undifferentiated spondyloarthropathy. Clin Exp Rheumatol 2002; 20 Suppl. 28: S126-9
7. Temekonidis TI, Alamanos Y, Nikas SN, et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis 2003; 62: 1218-20
8. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130: 478-86
9. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93
10. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9
11. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized trial. Lancet 2004; 363: 675-81
12. Smolen JS, van der Heijde D, St Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006; 54: 702-10
13. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37
14. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-11
15. Davis Jr JC, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48: 3230-6
16. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2264-72
17. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 3279-89
18. Ellerin T, Weinblatt ME. Infections and anti-tumor necrosis α therapy. Arthritis Rheum 2003; 48: 3013-22
19. Cunnane G, Doran M, Bresnihan B. Infections and biological therapy in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003; 17: 345-63
20. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85
21. Day R. Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis. Lancet 2002; 359: 540-1
22. Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J Rheumatol 2002; 29 Suppl. 65: 33-8
23. Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicentre-active surveillance report. Arthritis Rheum 2003; 48: 2122-7
24. Salmon D, GTI, AFSSAPS. Groupe Tuberculose et Infliximab. Agence Française de Sécurité Sanitaire de Produits de Santé. Recommendations about the prevention and management of tuberculosis in patients taking infliximab. Joint Bone Spine 2002; 69: 170-2
25. Harney S, O'Shea FD, Fitzgerald O. Peptostreptococcal pericarditis complicating anti-tumour necrosis factor alpha treatment in rheumatoid arthritis. Ann Rheum Dis 2002; 6: 653-4
26. Kroesen S, Widmer AF, Tyndall A, et al. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology 2003; 42: 617-21
27. Matzkies FG, Manger B, Schmitt-Haendle M, et al. Severe septicaemia in a patient with polychondritis and Sweet's syndrome after initiation of treatment with infliximab. Ann Rheum Dis 2003; 62: 81-2
28. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 3403-12
29. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines: guidelines for the management of rheumatoid arthritis. 2002 update. Arthritis Rheum 2002; 46: 328-46
30. Ledingham J, Deighton C, on behalf of the BSR Standards, Guidelines and Audit Working Group, et al. Update of the BSR guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology 2005; 44: 157-63
31. Gabriel SE, Crowson CS, O'Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985. Arthritis Rheum 1999; 42: 415-20
32. Harrison MJ, Kim CA, Silverberg M, et al. Does age bias the aggressive treatment of elderly patients with rheumatoid arthritis? J Rheumatol 2005; 32: 1243-8
33. Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46: 2294-300
34. Fleischmann RM, Baumgartner SW, Tindall EA, et al. Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. J Rheumatol 2003; 30: 691-6
35. Fleischmann RM, Baumgartner SW, Weisman M, et al. Long-term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis 2006; 65: 379-84
36. Bathon JM, Fleischmann RM, van der Heijde D, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol 2006; 33: 234-43
37. Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor a agents in rheumatoid arthritis. Arthritis Rheum 2003; 48: 313-8
38. Furst DE. Observational cohort studies and well controlled clinical trials: we need them both! J Rheumatol 2004; 31: 1476-7
39. Genevay S, Finckh A, Genta MS, et al. Efficacy and tolerance of TNF inhibitors in elderly patients with rheumatoid arthritis: a population based study [abstract no. SAT 0068]. Ann Rheum Dis 2005; 64 Suppl. III: 430
40. Salliot C, Gossec L, Ruyssen-Witrand A, et al. The risk of serious infections is higher in daily practice than in clinical trials for rheumatic patients receiving TNF blockers: a systematic retrospective study of 770 patients [abstract no. 858]. Arthritis Rheum 2005; 52 Suppl.: S340
41. Legrand JL, Solau-Gervais E, Vieillard MH, et al. Anti-TNF alpha chez le sujet âgé: profil des patients et toĺerance [abstract no. Lu.33]. Rev Rhum 2005; 72: 974
42. Chevillotte-Maillard E, Ornetti P, Mistrih R, et al. Survival and safety of treatment with infliximab in the elderly population. Rheumatology 2005; 44: 695-6
43. Maillard H, Ornetti P, Grimault L, et al. Severe pyogenic infections in patients taking infliximab: a regional cohort study. Joint Bone Spine 2005; 72: 330-4